Novartis (NYSE:NVS) announced on Tuesday, November 17, 2026, that the US Food and Drug Administration (FDA) had approved Cosentyx (secukinumab) for adults with polymyalgia rheumatica (PMR) who have experienced an inadequate response to corticosteroids or are unable to tolerate reductions in steroid treatment.
The approval covers the 150-mg dose of Cosentyx, making it the first and only biologic targeting interleukin-17 (IL-17) authorised in the United States for the inflammatory condition, according to the Swiss pharmaceutical company.
The decision represents the eleventh approved US indication for Cosentyx.
The FDA’s decision was supported by results from the Phase III REPLENISH clinical trial, which evaluated Cosentyx in patients with polymyalgia rheumatica across 27 countries.
The study compared 150-mg and 300-mg doses of secukinumab with placebo, alongside a corticosteroid reduction programme lasting 24 weeks.
At Week 52, sustained remission was achieved by 40.5% of patients receiving Cosentyx, compared with 20.5% of those assigned to placebo.
Novartis also reported that the study demonstrated a reduction in corticosteroid requirements among patients treated with Cosentyx.
The findings support the use of secukinumab as an additional treatment option for patients who have difficulty reducing steroid therapy or whose symptoms are not adequately controlled by existing treatment.
Polymyalgia rheumatica is an inflammatory condition that predominantly affects people aged 50 and older.
The disease is associated with pain and stiffness, particularly in the shoulders, neck and hips, and can interfere with everyday physical activities.
According to estimates provided by Novartis, approximately 966,000 people in the United States are living with PMR.
The company also reported that up to 40% of patients experience a relapse during the first year of treatment.
Corticosteroids are commonly used to manage the condition, although prolonged treatment can increase the risk of complications including osteoporosis, cardiovascular disease and diabetes.
The potential to reduce steroid exposure was therefore an important consideration in the REPLENISH trial.
Novartis said the overall safety profile observed in REPLENISH was consistent with the established safety characteristics of Cosentyx, although certain adverse events occurred more frequently among treated patients than those receiving placebo.
Hypersensitivity reactions were reported in 14% of patients receiving the 150-mg dose, compared with 9% in the placebo group.
Urinary tract infections occurred in 13% of patients treated with Cosentyx, against 7% of those receiving placebo.
One patient in the Cosentyx treatment group experienced a serious urinary tract infection, while one fatal case of cryptococcal meningitis was also reported during the study.
These findings formed part of the safety information assessed in connection with the regulatory review.
Novartis said Cosentyx had already received regulatory approval for polymyalgia rheumatica in the European Union.
Further regulatory assessments remain underway in other markets, including Japan.
The US authorisation expands the range of approved uses for secukinumab, which now has eleven indications in the country.
Novartis stock price
| 9 hours | |
| 12 hours | |
| 12 hours | |
| Nov-16 | |
| Nov-13 | |
| Nov-10 | |
| Nov-09 |
Trump's Plan to Lower Drug Prices in U.S. Is Leading to Fewer New Drugs in Europe
NVS
The Wall Street Journal
|
| Nov-07 | |
| Nov-02 | |
| Nov-02 | |
| Oct-30 | |
| Oct-30 | |
| Oct-30 | |
| Oct-28 | |
| Oct-27 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite